Under the terms of the collaboration, L'Oréal will conduct formulation and research studies, expected to begin in early 2018, to evaluate the potential of SM05253 in anti-wrinkle skin care applications.
“The prospect of L'Oréal, the world’s leading beauty company, further developing SM05253 for skin care applications, presents us with a compelling opportunity to capitalize on a valuable, non-core asset,” said Erich Horsley, Chief Business Officer of Samumed. “L'Oréal’s expertise in research and development of skin care compounds, combined with its global footprint, makes it an ideal partner to assume the development of SM05253.”
Samumed says its small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. The company is also involved in psoriasis treatments. Samumed’s clinical pipeline can be found here: www.samumed.com/pipeline